Browse Clinical Trials: Cell-Based Therapies for COVID-19

NCT04798066	Intermediate Size Expanded Access Protocol Evaluating HB-adMSC's for the Treatment of Post-COVID-19 Syndrome	Available	Biological: Autologous HB-adMSC's	Hope Biosciences Stem Cell Research Foundation\|Hope Biosciences		0	USA
NCT04293692	Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus	Withdrawn	UC-MSCs\|Placebo	Puren Hospital Affiliated to Wuhan University of Science and Technology\|Wuhan Hamilton Bio-technology Co., Ltd	Not Applicable	0	China
NCT04341610	ASC Therapy for Patients With Severe Respiratory COVID-19	Withdrawn	Stem Cell Product	Rigshospitalet, Denmark	Phase 1\|Phase 2	0	Denmark
NCT04805086	The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19	Recruiting	Biological: MON002	Guy's and St Thomas' NHS Foundation Trust\|King's College London	Phase 1\|Phase 2	5	UK
NCT04513470	Allocetra-OTS in COVID-19	Recruiting	Allocetra-OTS	Hadassah Medical Organization	Phase 1	5	Israel
NCT04313322	Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells	Recruiting	WJ-MSCs	Stem Cells Arabia	Phase 1	5	Jordan
NCT04522986	An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection	Not yet recruiting	Mesenchymal stem cell	Rohto Pharmaceutical Co., Ltd.	Phase 1	6	Japan
NCT04400032	Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard	Not yet recruiting	Mesenchymal Stromal Cells	Ottawa Hospital Research Institute\|Stem Cell Network	Phase 1	9	Canada
NCT04331613	Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS	Recruiting	CAStem	Chinese Academy of Sciences\|Beijing YouAn Hospital	Phase 1\|Phase 2	9	China
NCT04452097	Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS	Not yet recruiting	Human umbilical cord mesenchymal stem cells + best supportive care	Baylx Inc.	Phase 1	9	Colombia
NCT04535856	Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients	Not yet recruiting	Allogeneic mesenchymal stem cell\|Placebo	Ina-Respond\|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia\|Daewoong Pharmaceutical Co. LTD.	Phase 1	9	Indonesia
NCT04456361	Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19	Active, not recruiting	Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords	Instituto de Medicina Regenerativa	Early Phase 1	9	Mexico
NCT04447833	Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome	Recruiting	Mesenchymal Stromal Stem Cells - KI-MSC-PL-205	Uppsala University\|Uppsala University Hospital	Phase 1	9	Sweden
NCT04467047	Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19	Not yet recruiting	Mesenchymal Stromal Cells infusion	Hospital de Clinicas de Porto Alegre	Phase 1	10	Brazil
NCT04344548	Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia	Not yet recruiting	Allogeneic NK transfer	Universidad Nacional de Colombia\|Fundación Salud de los Andes	Phase 1\|Phase 2	10	Colombia
NCT04416139	Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19	Recruiting	Infusion IV of Mesenchymal Stem cells	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	Phase 2	10	Mexico
NCT04527224	Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia	Not yet recruiting	AstroStem-V	Nature Cell Co. Ltd.	Phase 1\|Phase 2	10	South Korea
NCT04397471	A Study to Collect Bone Marrow for Process Development and Production of BM-MSC to Treat Severe COVID19 Pneumonitis	Not yet recruiting	Bone Marrow Harvest	CCTU- Cancer Theme\|Cambridge Cellular Therapies Laboratory\|The Evelyn Trust\|Cambridge University Hospitals NHS Foundation Trust		10	United Kingdom
NCT04319731	A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure	Recruiting	Human Amniotic Fluid	University of Utah	Early Phase 1	10	USA
NCT04646603	MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients	Not yet recruiting	MRG-001\|Drug: Placebo	MedRegen LLC\|Kendall Healthcare Group, Ltd.	Phase 1\|Phase 2	12	USA
NCT04742595	SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer	Recruiting	Biological: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes	M.D. Anderson Cancer Center	Early Phase 1	16	USA
NCT04269525	Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia	Recruiting	UC-MSCs	ZhiYong Peng\|Tuohua Biological Technology Co. Ltd\|Zhongnan Hospital	Phase 2	16	China
NCT04457726	Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19	Recruiting	SARS-CoV-2 Specific T Cells	KK Women's and Children's Hospital\|Duke-NUS Graduate Medical School\|National University Hospital, Singapore\|Singapore General Hospital\|Sengkang General Hospital\|Changi General Hospital	Phase 1\|Phase 2	18	Singapore
NCT04737161	Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome	Not yet recruiting	Biological: T regulatory cells	Stanford University	Phase 1	20	USA
NCT04445454	Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection	Recruiting	Mesenchymal stromal cells	University of Liege	Phase 1\|Phase 2	20	Belgium
NCT04525378	MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome	Recruiting	Mesenchymal stromal cell-based therapy	D'Or Institute for Research and Education	Phase 1	20	Brazil
NCT04451291	Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure	Not yet recruiting	Decidual Stromal Cells (DSC)	University Health Network, Toronto\|Oslo University Hospital	Not Applicable	20	Canada
NCT04252118	Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19	Recruiting	MSCs	Beijing 302 Hospital\|Innovative Precision Medicine Group (IPM), Hangzhou, China.\|Huoshenshan Hospital\|Tianjin Haihe Hospital\|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China\|Shenzhen Third People's Hospital\|Fifth Affiliated Hospital, Sun Yat-Sen University	Phase 1	20	China
NCT04336254	Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients	Recruiting	Allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)\|Intravenous saline injection (Placebo)	Renmin Hospital of Wuhan University\|Beijing SH Bio-Tech Corporation, Beijing (CN)\|Utooth Biological Technology Co., Ltd. Hubei (CN)	Phase 1\|Phase 2	20	China
NCT04346368	Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)	Not yet recruiting	BM-MSCs\|Placebo	Guangzhou Institute of Respiratory Disease\|Guangzhou Eighth People's Hospital\|Tongji Hospital, Huazhong University of Science & Technology\|Guangzhou Cellgenes Biotechnology Co.,Ltd	Phase 1\|Phase 2	20	China
NCT04611256	Mesenchymal Stem Cells in Patients Diagnosed With COVID-19	Recruiting	MSC\|Drug: Control	Hospital Reg. Lic. Adolfo Lopez Mateos\|Instituto de Terapia Celular: ITC	Phase 1	20	Mexico
NCT04444271	Mesenchymal Stem Cell Infusion for COVID-19 Infection	Recruiting	Mesenchymal stem cells\|Placebo	Dr. Zaineb Akram\|National Institute of Blood and Marrow Transplant (NIBMT), Pakistan	Phase 2	20	Pakistan
NCT04437823	Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients	Recruiting	Intravenous Infusions of Stem Cells	Jinnah Hospital\|Johns Hopkins University	Phase 2	20	Pakistan
NCT04615429	Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19	Recruiting	Mesenchymal stromal cells\|Other: Placebo	Cristina AvendaÃ±o SolÃ¡\|Puerta de Hierro University Hospital	Phase 2	20	Spain
NCT04299152	Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19	Not yet recruiting	Stem Cell Educator-Treated Mononuclear Cells Apheresis	Tianhe Stem Cell Biotechnologies Inc.	Phase 2	20	USA
NCT04352803	Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease	Not yet recruiting	Autologous Adipose MSC's	Regeneris Medical	Phase 1	20	USA
NCT04384445	Organicell Flow for Patients With COVID-19	Not yet recruiting	Organicell Flow\|Placebo	Organicell Regenerative Medicine	Phase 1\|Phase 2	20	USA
NCT04401410	Anti-SARS Cov-2 T Cell Infusions for COVID 19	Not yet recruiting	Partially HLA-matched Virus Specific T cells (VSTs)	Baylor College of Medicine\|Center for Cell and Gene Therapy, Baylor College of Medicine\|The Methodist Hospital System\|AlloVir	Phase 1	20	USA
NCT04713878	Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia	Completed	Other: Mesenchymal stem cells	Kanuni Sultan Suleyman Training and Research Hospital	Not Applicable	21	Turkey
NCT04490486	Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19	Not yet recruiting	UCMSCs\|Placebo	Joshua M Hare\|University of Miami	Phase 1	21	USA
NCT04445220	A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy	Not yet recruiting	SBI-101	Sentien Biotechnologies, Inc.	Phase 1\|Phase 2	22	USA
NCT04765449	Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection	Not yet recruiting	Drug: Cytotoxic T Lymphocytes	Thomas Jefferson University\|Tevogen Bio Inc	Phase 1	24	USA
NCT04537351	The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19	Recruiting	CYP-001	Cynata Therapeutics Limited\|Cerebral Palsy Alliance Research Institute	Phase 1\|Phase 2	24	Australia
NCT04634370	Fase I Clinical Trial on NK Cells for COVID-19	Not yet recruiting	Natural Killer Cells infusion	Hospital de Clinicas de Porto Alegre	Phase 1	24	Brazil
NCT04302519	Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells	Not yet recruiting	Dental pulp mesenchymal stem cells	CAR-T (Shanghai) Biotechnology Co., Ltd.	Early Phase 1	24	China
NCT04590053	Allocetra-OTS in COVID-19, Phase II	Recruiting	Allocetra-OTS	Hadassah Medical Organization\|Barzilai Medical Center\|Tel-Aviv Sourasky Medical Center	Phase 2	24	Israel
NCT04361942	Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)	Recruiting	Mesenchymal Stromal Cells\|Placebo	Red de Terapia Celular\|Citospin\|University of Valladolid\|Castilla-León Health Service\|Hospital del Río Hortega\|Instituto de Salud Carlos III	Phase 2	24	Spain
NCT04355728	Use of UC-MSCs for COVID-19 Patients	Active, not recruiting	Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care\|Vehicle + Heparin along with best supportive care	Camillo Ricordi\|University of Miami	Phase 1\|Phase 2	24	USA
NCT04366323	Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19	Recruiting	Allogeneic and Expanded Adipose Tissue-Derived Mesenchymal Stem Cells	Andalusian Network for Design and Translation of Advanced Therapies	Phase 1\|Phase 2	26	Spain
NCT04747574	Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection	Recruiting	Drug: EXO-CD24	Tel-Aviv Sourasky Medical Center	Phase 1	30	Israel
NCT04760184	Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden	Not yet recruiting	Other: Autologous stem cell transplantation	Uppsala University\|Karolinska University Hospital\|Sahlgrenska University Hospital, Sweden\|Lund University Hospital\|University Hospital, Linkoeping\|University Hospital, UmeÃ¥\|Region Ã–rebro County\|Uppsala University Hospital	Observational	30	Sweden
NCT04276987	A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia	Not yet recruiting	MSCs-derived exosomes	Ruijin Hospital\|Shanghai Public Health Clinical Center\|Wuhan Jinyintan Hospital, Wuhan, China\|Cellular Biomedicine Group Ltd.	Phase 1	30	China
NCT04280224	NK Cells Treatment for COVID-19	Recruiting	NK Cells	Xinxiang medical university\|First Affiliated Hospital of Xinjiang Medical University	Phase 1	30	China
NCT04339660	Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia	Recruiting	UC-MSCs\|Placebo	Puren Hospital Affiliated to Wuhan University of Science and Technology\|Shanghai University\|Qingdao Co-orient Watson Biotechnology group co. LTD\|Basic Medical Sciences, Chinese Academy of Medical Sciences	Phase 1\|Phase 2	30	China
NCT04429763	Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia	Not yet recruiting	Umbilical cord derived mesenchymal stem cells\|Placebo	Trustem\|Fundación Universitaria de Ciencias de la Salud\|Hospital de San Jose\|Hospital Infantil Universitario de San Jose	Phase 2	30	Colombia
NCT04625738	Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome	Not yet recruiting	Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells\|Biological: Placebo	Central Hospital, Nancy, France	Phase 2	30	France
NCT04390139	Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19	Recruiting	Drug: XCEL-UMC-BETA\|Other: Placebo	Banc de Sang i Teixits	Phase 1\|Phase 2	30	Spain
NCT04392778	Clinical Use of Stem Cells for the Treatment of Covid-19	Recruiting	MSC Treatment\|Saline Control	SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi\|Istinye University\|Regenerative Medicine and Stem Cell Production Center Liv MedCell\|Liv Hospital (Ulus)	Phase 1\|Phase 2	30	Turkey
NCT04461925	Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs	Recruiting	Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells\|Antibiotics\|Hormones\|Anticoagulant Therapy\|Oxygen therapy	Institute of Cell Therapy\|Kyiv City Clinical Hospital # 4	Phase 1\|Phase 2	30	Ukraine
NCT04345601	Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)	Not yet recruiting	Mesenchymal Stromal Cells\|Supportive Care	Baylor College of Medicine\|Center for Cell and Gene Therapy, Baylor College of Medicine\|The Methodist Hospital System	Early Phase 1	30	USA
NCT04399889	hCT-MSCs for COVID19 ARDS	Recruiting	human cord tissue mesenchymal stromal cells	Joanne Kurtzberg, MD\|The Marcus Foundation\|Duke University	Phase 1\|Phase 2	30	USA
NCT04466098	Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)	Recruiting	Mesenchymal stromal cells\|Placebo	Masonic Cancer Center, University of Minnesota	Phase 2	30	USA
NCT04716998	Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19	Recruiting	Biological: MesenCure	BonusBio Group Ltd	Phase 1\|Phase 2	35	Israel
NCT04780685	A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19	Recruiting	Biological: hMSC	Stemedica Cell Technologies, Inc.\|bioRASI, LLC	Phase 2	40	USA
NCT04382547	Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells	Enrolling by invitation	Allogenic pooled olfactory mucosa-derived mesenchymal stem cells\|Standard treatment according to the Clinical protocols	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus\|Belarusian State Medical University	Phase 1\|Phase 2	40	Belarus
NCT04390152	Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19	Not yet recruiting	Wharton's jelly derived Mesenchymal stem cells.\|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)	BioXcellerator\|Clinical Somer	Phase 1\|Phase 2	40	Colombia
NCT04333368	Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS	Recruiting	Umbilical cord Wharton's jelly-derived human\|NaCl 0.9%	Assistance Publique - Hôpitaux de Paris	Phase 1\|Phase 2	40	France
NCT04377334	Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)	Not yet recruiting	MSC	University Hospital Tuebingen	Phase 2	40	Germany
NCT04614025	Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19	Recruiting	PLX-PAD	Pluristem Ltd.	Phase 2	40	Germany
NCT04457609	Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients	Recruiting	Oseltamivir\|Drug: Azithromycin\|Biological: Umbilical Cord Mesenchymal Stem Cells	Indonesia University	Phase 1	40	Indonesia
NCT04573270	Mesenchymal Stem Cells for the Treatment of COVID-19	Completed	PrimePro\|Placebo	Thomas Advanced Medical LLC\|HeartStem Institute	Phase 1	40	USA
NCT04397796	Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation	Recruiting	BM-Allo.MSC\|Placebo	NantKwest, Inc.	Phase 1	45	USA
NCT04753476	Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia	Recruiting	Biological: Injection of Secretome-MSCs\|Drug: Standard treatment of Covid-19	Stem Cell and Cancer Research Indonesia\|Provincial Government of Central Java, Indonesia	Phase 2	48	Indonesia
NCT04273646	Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19	Not yet recruiting	UC-MSCs\|Placebo	Wuhan Union Hospital, China\|Wuhan Hamilton Bio-technology Co., Ltd, China.	Not Applicable	48	China
NCT04659304	Study Evaluating Safety, Tolerability and Efficacy of Allocetra-OTS in Patients With COVID-19	Not yet recruiting	Allocetra-OTS\|Other: Ringer's lactate	Enlivex Therapeutics Ltd.	Phase 1	50	Israel
NCT04797975	Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19	Not yet recruiting	Biological: KDS-1000\|Other: Placebo	Kiadis Pharma	Phase 1\|Phase 2	54	Netherlands
NCT04798716	The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19	Not yet recruiting	Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)\|Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)\|Drug: MSC-exosomes delivered intravenously every other day (8:8:8)	AVEM HealthCare	Phase 1\|Phase 2	55	USA
NCT04349631	A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19	Enrolling by invitation	HB-adMSCs	Hope Biosciences	Phase 2	56	USA
NCT04578210	Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia	Recruiting	T memory cells and NK cells	Instituto de Investigación Hospital Universitario La Paz\|Universidad Autonoma de Madrid\|Universidad Miguel Hernandez de Elche\|Asociación Instituto de Investigación Sanitaria BioCruces\|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana	Phase 1\|Phase 2	58	Spain
NCT04371601	Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019	Active, not recruiting	Drug: Oseltamivir\|Drug: hormones\|Device: oxygen therapy\|Procedure: mesenchymal stem cells	Fuzhou General Hospital	Early Phase 1	60	China
NCT04639440	Impact of Adipose Tissue in COVID-19	Not yet recruiting	Other: Adipose tissue	Assistance Publique - HÃ´pitaux de Paris		60	France
NCT04366063	Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome	Recruiting	Cell therapy protocol 1\|Cell therapy protocol 2	Royan Institute\|Tehran University of Medical Sciences\|Shahid Beheshti University of Medical Sciences	Phase 2\|Phase 3	60	Iran
NCT04389385	COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)	Active, not recruiting	COVID-19 Specific T Cell derived exosomes (CSTC-Exo)	TC Erciyes University	Phase 1	60	Turkey
NCT04494386	Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS	Recruiting	Umbilical Cord Lining Stem Cells (ULSC)\|Placebo (carrier control)	Restem, LLC.	Phase 1\|Phase 2	60	USA
NCT04623671	Intravenous Infusion of CAP-1002 in Patients With COVID-19	Recruiting	CAP-1002\|Biological: Placebo	Capricor Inc.	Phase 2	60	USA
NCT04398303	ACT-20 in Patients With Severe COVID-19 Pneumonia	Not yet recruiting	ACT-20-MSC\|ACT-20-CM\|Placebo	Aspire Health Science	Phase 1\|Phase 2	70	USA
NCT04565665	Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome	Recruiting	Best Practice\|Mesenchymal Stem Cell	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Phase 1	70	USA
NCT04629105	Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER)	Recruiting	Longeveron Mesenchymal Stem Cells (LMSCs)\|Other: Placebo	Longeveron LLC	Phase 1	70	USA
NCT03042143	Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)	Recruiting	Human Umbilical Cord Derived CD362 Enriched MSCs\|Placebo (Plasma-Lyte 148)	Belfast Health and Social Care Trust\|Queen's University, Belfast\|Northern Ireland Clinical Trials Unit\|NHS Blood and Transplant	Phase 1\|Phase 2	75	UK
NCT04365101	Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19)	Recruiting	CYNK-001	Celularity Incorporated\|IDRI\|Lung Biotechnology PBC\|California Institute for Regenerative Medicine (CIRM)	Phase 1\|Phase 2	86	USA
NCT04482699	RAPA-501-Allo Off-the-Shelf Therapy of COVID-19	Not yet recruiting	RAPA-501-Allo off-the-shelf Therapy of COVID-19\|Placebo	Rapa Therapeutics LLC\|Hackensack Meridian Health	Phase 1\|Phase 2	88	USA
NCT04315987	NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia	Not yet recruiting	NestaCell®\|Placebo	Azidus Brasil\|Cellavita Pesquisa Científica Ltda\|Hospital Vera Cruz	Phase 2	90	Brazil
NCT04324996	A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19	Recruiting	NK cells, IL15-NK cells, NKG2D CAR-NK cells, ACE2 CAR-NK cells, NKG2D-ACE2 CAR-NK cells	Chongqing Public Health Medical Center\|Chongqing Sidemu Biotechnology Technology Co.,Ltd.	Phase 1\|Phase 2	90	China
NCT04602442	Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia	Enrolling by invitation	EXO 1 inhalation\|Drug: EXO 2 inhalation\|Drug: Placebo inhalation	Olga Tyumina\|Clinics of the Federal State Budgetary Educational Institution SSMU\|Samara Regional Clinical Hospital V.D. Seredavin\|State-Financed Health Facility "Samara Regional Medical Center Dinasty"	Phase 2	90	Russia
NCT04728698	Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress	Not yet recruiting	Drug: COVI-MSC\|Drug: Placebo	Sorrento Therapeutics, Inc.	Phase 2	100	USA
NCT04288102	Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)	Active, not recruiting	UC-MSCs\|Saline containing 1% Human serum albumin (solution without UC-MSCs)	Beijing 302 Hospital\|Huoshenshan Hospital\|Maternal and Child Health Hospital of Hubei Province\|General Hospital of Central Theater Command, Wuhan, China\|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China	Phase 2	100	China
NCT04393415	Using PRP and Cord Blood in Treatment of Covid -19	Recruiting	Stem cells	Aljazeera Hospital	Not Applicable	100	Egypt
NCT04348461	BAttLe Against COVID-19 Using MesenchYmal Stromal Cells	Not yet recruiting	Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz\|Instituto de Investigación Sanitaria y Biomédica de Alicante\|Hospital General Universitario Gregorio Marañon\|Clinica Universidad de Navarra, Universidad de Navarra\|Hospital Universitario de Salamanca\|Hospital General Universitario de Alicante\|Hospital Clínico Universitario Virgen de la Arrixaca	Phase 2	100	Spain
NCT04348435	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19	Enrolling by invitation	HB-adMSCs\|Placebos	Hope Biosciences\|Hope Biosciences Stem Cell Research Foundation	Phase 2	100	USA
NCT04406064	Viral Specific T-cells for Treatment of COVID-19	Not yet recruiting	Viral Specific T-cells (VSTs)	Children's Hospital Medical Center, Cincinnati\|Hoxworth Blood Center	Phase 2	100	USA
NCT04362189	Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19	Active, not recruiting	HB-adMSC\|Placebo	Hope Biosciences\|Advanced Diagnostics Healthcare\|Hope Biosciences Stem Cell Research Foundation\|United Memorial Medical Center	Phase 2	100	USA
NCT04366271	Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19	Recruiting	Mesenchymal cells\|Standard of care	Hospital Infantil Universitario Niño Jesús, Madrid, Spain\|Apices Soluciones S.L.	Phase 2	106	Spain
NCT04724642	COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency	Recruiting		Tel-Aviv Sourasky Medical Center	Observational	110	Israel
NCT04590261	Myeloid Cells in Patients With Covid-19 Pneumonia	Not yet recruiting	Blood sampling\|Nasal Brushing	Assistance Publique - Hôpitaux de Paris\|Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France	Not Applicable	120	France
NCT04389450	Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19	Recruiting	PLX-PAD\|Placebo	Pluristem Ltd.	Phase 2	140	USA
NCT04473170	Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19	Completed	Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)\|COVID-19 standard care	Abu Dhabi Stem Cells Center	Phase 1\|Phase 2	146	UAE
NCT04428801	Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19	Not yet recruiting	Autologous adipose-derived stem cells	Celltex Therapeutics Corporation	Phase 2	200	USA
NCT04371393	MSCs in COVID-19 ARDS	Recruiting	Remestemcel-L\|Placebo	Icahn School of Medicine at Mount Sinai\|Mesoblast, Inc.	Phase 3	300	USA
NCT04367077	MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)	Recruiting	MultiStem\|Placebo	Athersys, Inc	Phase 2\|Phase 3	400	USA
NCT04657406	Expanded Access to ZofinTM (OrganicellTM Flow) for Patients With COVID-19	Available	ZofinTM (OrganicellTM Flow)		Organicell Regenerative Medicine\|bioRASI, LLC	Expanded Access
NCT04657458	Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS	Available	Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment		Direct Biologics, LLC	Expanded Access
NCT04338347	CAP-1002 in Severe COVID-19 Disease	Available	CAP-1002 Allogeneic Cardiosphere-Derived Cells	Capricor Inc.			USA
NCT04366830	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection	No longer available	Remestemcel-L	Mesoblast International Sàrl\|Mesoblast, Ltd.			USA
NCT04456439	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)	Available	Remestemcel-L\|Drug: Hydrocortisone\|Drug: Diphenhydramine	Mesoblast International SÃ rl\|Mesoblast, Ltd.			USA

Browse Clinical Trials: Cell-Based Therapies for COVID-19

Signup for Updates

Success!